The Role of Somatostatin-Receptor Scintigraphy in the Diagnosis and Staging of Pulmonary Carcinoid Tumors

Walid Abu Arab1,2*, Yves Collin1, Marco Sirois1, Marc-André Levasseur3 and Nancy Paquet3

1Department of Medicine, University of Sherbrooke, Canada
2Department of Cardiothoracic Surgery, University of Alexandria, Egypt
3Department of Nuclear Medicine, University of Sherbrooke, Canada

Abstract

Background: Carcinoid tumors are rare low grade neuroendocrine tumors which rarely affect the lung. Somatostatin - receptor scintigraphy (Octreo-scan) can be helpful in the diagnosis and staging when the tumor is located in the gastro-intestinal tract (GI-tract). However, there is a few data in the literature regarding its role in the diagnosis of pulmonary carcinoids. The aim of this study is to assess the clinical utility of Somatostatin Receptor Scintigraphy (SRS) [OctreoScan**] in the diagnosis and staging of pulmonary carcinoids and its role in the treatment plan of the patients.

Methods: This is a retrospective clinical study that included the patients with pulmonary carcinoid tumors who underwent lung resection at Centre HospitalierUniversitaire de Sherbrooke (CHUS), Canada between 2004 and 2014. The files of those patients have been reviewed. Data collected included the demographic data, methods of diagnosis, pathology, staging work-up as well as costs of the effectuated investigations. Statistical analysis of was performed using Microsoft Excel 2007.

Results: Sixteen patients were included in this study. SRS was performed for eight of them, and it was positive in seven patients (87% sensitivity). On contrast, Positive Emission Tomography (PET-scan) was found to have 76% sensitivity. The cost was 1100 CAN$ for PET-scan and 2000 CAN$ for SRS. Radiation dose equivalence were comparable for both exams.

Conclusions: The SRS is a valuable method to detect and stage pulmonary carcinoid tumors. We believe that it should be the method of choice for a diagnosis and staging when pulmonary carcinoid tumor is suspected.

Keywords: Lung Cancer; Diagnosis of carcinoma; Neuroendocrine; Neuroendocrine tumor; Positron Emission Tomography PET; Octreoscan; SRS

Introduction

Neuroendocrine tumors (NET) are tumors that originate from neural crest cells throughout the body. Carcinoid tumors are low grade malignant NETs with metastatic potential. Symptoms that are caused by carcinoid tumors are due to hormonal excess, local tumor growth, or metastasis. Surgical resection is the curative treatment for the localized disease [1-3]. Some authors classified pulmonary NETs into four categories: 1) typical carcinoid (also called bronchial carcinoid tumor, Kulchitsky cell carcinoma (KCC-I); 2) atypical carcinoid (also called well-differentiated neuroendocrine carcinoma, KCC-II); 3) intermediate small cell neuroendocrine carcinoma; and 4) small cell carcinoma (KCCIII). Another proposed classification includes three categories of lung NETs: benign (typical carcinoid), low-grade malignant (atypical carcinoid), and high-grade malignant (poorly differentiated carcinoma of the large cell or small cell type) [2-4]. Atypical carcinoid tumors metastasize more commonly to the regional lymph nodes. The overall 5-year survival for atypical carcinoid tumors ranges between 40 to 69 % versus 87 to 100 % for the typical carcinoids [5]. NET cells can synthesize and secrete a variety of physiologically active peptides that are able to generate different clinical symptoms. The most common symptoms include flushing and diarrhea, which result from synergistic interactions between 5-HTP (5- Hydroxytryptamine) metabolites, kinins, and prostaglandins. This is known as carcinoid syndrome [1-3]. Carcinoid syndrome is rarely encountered in pulmonary carcinoid tumors [5-7]. The common feature for the majority of NETs is the expression of somatostatin peptide receptors (SSRs). This characteristic feature is employed for diagnostic imaging, using a radio-labeled somatostatin analog (Indium-111 octreotide). Somatostatine receptor scintigraphy could be helpful to assess the extent of the tumor...
spread in order to evaluate proper surgical treatment. Kwekkeboom et al. [8] documented that the combination of somatostatin receptor scintigraphy and other diagnostic tools can improve the staging process of the carcinoid tumors. Somatostatin-receptor scintigraphy (SRS; Octreoscan®, Mallinckrodt, Petten, The Netherlands) is performed by injecting a dose of radioisotope such as (111In-DTPA0) octreotide or (111In-pentetreotide) that could bind to the two most prevalent somatostatin receptors found on NETs (sst2 and sst5); this allows visualization and localization of NETs [9,10]. The use of SRS could be an option for detection and staging of pulmonary NETs. Nevertheless, SRS is currently rarely used for this purpose. We hypothesized that it should have a more important role in the workup for patients who have these type of tumors.

**Patients and Methods**

A retrospective study protocol was approved by the Ethics Committee of the Centre de Recherche Étienne-Lebel at Centre Hospitalier Universitaire de Sherbrooke (CHUS), Canada. All patients with confirmed pulmonary carcinoid tumor who were operated at our center during the period between 2004 and 2012 were included in this study. The patients’ files were systematically reviewed. Data concerning Patients’ age, sex, respiratory function test, clinical presentation, pathology, diagnostic methods as well as their costs and their radiation doses were obtained. The results were arranged into three groups according to whether an SRS was performed and was found positive (Group I); SRS was done and was found negative (Group II); or the SRS was not done at all (Group III).

**Results**

Sixteen patients (37% male, 63% female) were included in this study. Age ranged between 37-78 years with a mean of 59 years (Table 1). Three patients were smokers. Eight patients were asymptomatic (50%). Seven patients (43%) presented with pulmonary symptoms. The most frequent symptoms were cough and hemoptysis; while Cushing’s syndrome was met with in one patient (6.25%) Pathological symptoms were seen in patients with severe tumors.

Table 1: Patient’s distribution.

<table>
<thead>
<tr>
<th>No.</th>
<th>Sex</th>
<th>Age</th>
<th>Presentation</th>
<th>Imaging Type</th>
<th>Pathology</th>
<th>Lymphadenopathy</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M</td>
<td>53</td>
<td>S</td>
<td>PET-Scan</td>
<td>Typical</td>
<td>Positive</td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>59</td>
<td>P</td>
<td>None</td>
<td>Typical</td>
<td>Positive</td>
</tr>
<tr>
<td>3</td>
<td>F</td>
<td>61</td>
<td>A</td>
<td>OCTREOSCAN</td>
<td>Atypical</td>
<td>Positive</td>
</tr>
<tr>
<td>4</td>
<td>F</td>
<td>46</td>
<td>P</td>
<td>PET-Scan</td>
<td>Typical</td>
<td>Negative</td>
</tr>
<tr>
<td>5</td>
<td>F</td>
<td>65</td>
<td>A</td>
<td>PET-Scan</td>
<td>Atypical</td>
<td>Positive</td>
</tr>
<tr>
<td>6</td>
<td>M</td>
<td>53</td>
<td>P</td>
<td>PET-Scan</td>
<td>Atypical</td>
<td>Positive</td>
</tr>
<tr>
<td>7</td>
<td>F</td>
<td>60</td>
<td>A</td>
<td>CT- Chest</td>
<td>Atypical</td>
<td>Negative</td>
</tr>
<tr>
<td>8</td>
<td>F</td>
<td>37</td>
<td>A</td>
<td>PET-Scan</td>
<td>Typical</td>
<td>Negative</td>
</tr>
<tr>
<td>9</td>
<td>F</td>
<td>42</td>
<td>A</td>
<td>PET-Scan</td>
<td>Atypical</td>
<td>Positive</td>
</tr>
<tr>
<td>10</td>
<td>F</td>
<td>44</td>
<td>P</td>
<td>PET-Scan</td>
<td>Atypical</td>
<td>Negative</td>
</tr>
<tr>
<td>11</td>
<td>F</td>
<td>76</td>
<td>P</td>
<td>PET-Scan</td>
<td>Typical</td>
<td>Negative</td>
</tr>
<tr>
<td>12</td>
<td>F</td>
<td>59</td>
<td>A</td>
<td>PET-Scan</td>
<td>Typical</td>
<td>Negative</td>
</tr>
<tr>
<td>13</td>
<td>M</td>
<td>74</td>
<td>A</td>
<td>PET-Scan</td>
<td>Typical</td>
<td>Negative</td>
</tr>
<tr>
<td>14</td>
<td>M</td>
<td>60</td>
<td>A</td>
<td>PET-Scan</td>
<td>Typical</td>
<td>Negative</td>
</tr>
<tr>
<td>15</td>
<td>F</td>
<td>73</td>
<td>P</td>
<td>PET-Scan</td>
<td>Typical</td>
<td>Negative</td>
</tr>
<tr>
<td>16</td>
<td>M</td>
<td>78</td>
<td>P</td>
<td>PET-Scan</td>
<td>Atypical</td>
<td>Negative</td>
</tr>
</tbody>
</table>

M = Male, F = Female, S = Systemic symptoms, A = Asymptomatic, P = Pulmonary symptoms
diagnosis was obtained through bronchoscopy in 37.5% of patients and through definitive surgery in 37.5% of them. Trans-thoracic needle biopsy was used as a diagnostic method in 25% of patients. Typical carcinoids tumors were found in 56% of the subjects while atypical carcinoids were found in the remaining 44% of patients. Five patients of sixteen patients (31.2%) had mediastinal lymph node metastasis.

**Sensitivity**

Eight patients out of the sixteen had a SRS beside PET-Scan. SRS was positive in seven patients (87.5%) while PET-Scan was positive in 78.6% of patients (11 patients) (Table 2). In the group 1 (SRS done and positive) (7 patients), only 57% of them had positive PET-scan (Table 3). Therefore, PET-scan missed 43% of the tumors.

**Comparison between Octreoscan and PET-scan positivity**

Octreoscan was positive in 43% of male patients and in 57% female patients. Meanwhile, PET-Scan was positive in 27% of male patients. Lung function was comparable in both groups. Metastatic adenopathies were found in 43% of positive Octreoscan at final pathology, while it was found to be 27% with the PET-Scan.

**Radiation level**

Mean radioactivity emission was 350.5 ± 47.6 MBq for PET-Scan and 134.14 ± 26.7 MBq for SRS. When corrected for dose equivalencies, emission for PET- scan was 6.7 mSv ± 0.9 while it was 7.3 ± 1.6 mSv for SRS.

**Costs**

The cost for the investigations in our center (CHUS-Canada) was estimated to be 1965.00CAN$ for SRS and 1160.00CAN$ for PET-scan. A quick review of the literature revealed a cost of 20 000US$ for SRS and 11 000US$ for PET-scan in the United States of America.

**Discussion**

The overall sensitivity of SRS in this study was slightly higher than that of PET-scan, which is consistent with the published data in the literature [11]. This is explained by the fact that while PET-scan relies on metabolic activity for imaging purposes; which is low in carcinoids; SRS relies on somatostatin receptors which are found in more than 80% of carcinoid tumors [9,12]. Moreover, PET-scan was only positive in 57% of patients in whom SRS was also positive. This result led to the conclusion that when a diagnosis of pulmonary carcinoid tumor is confirmed or is highly suspected, SRS could be the imaging modality of choice for localization and staging purposes. Since the radiation equivalence of both exams is comparable, patients should not suffer from that change of attitude. Furthermore, even though SRS is more costly, we believe that; by using a single workup exam instead of two; as it is actually the case when PET scan is negative; the cost effectiveness of SRS could be better. Nevertheless, SRS is not the only trustable modality as it is shown by the one negative result in our series. Since PET-scan came out positive in that particular case, we think that PET-scan imaging still has place in the work-up of carcinoid tumors if SRS is negative. Since we only reviewed cases of pulmonary carcinoids, we still recommend PET-scan as a primordial imaging modality in the diagnosis, staging and pre-operative planning of other types of lung nodules. We propose here an algorithm to clearly state the role of SRS in the management of pulmonary carcinoids (Figure 1). It is interesting to note that the proportion of smokers in our study was very low, which is consistent with the fact that smoking only has a marginal effect on the development of lung carcinoids [13]. Even with the small number of patients that were included in our study, we some tendencies in the group 1 were detected compared to positive PET-scan. Namely, male proportion that was higher. Final pathology reports showed more typical carcinoids but also more positive adenopathies. These results seem contradictory since typical carcinoids are usually less aggressive and have a lesser tendency to metastasize. It was believed that further studies should be performed to verify the predictors of sensibility for both SRS and PET-scan in patients with pulmonary carcinoids. This study has few limitations. First one is that the study is retrospective one and non-blinded but since we included every patient operated for lung carcinoid tumor during the period of the study, we don’t think that the retrospective nature of the work induced any bias. Second, the sample size is small, a fact inherent with research performed for rare diseases as pulmonary carcinoid tumors. This may led to statistical bias to some extent. Consequent to the previously mentioned reasons, it is recommended to perform further randomized prospective studies in the future to better clarify the results of our group.

**Conclusion**

The SRS is a diagnostic tool that can be helpful in pulmonary carcinoids. It can help to better localize and to precise the staging of the tumor. SRS could become the imaging modality of choice when suspecting a diagnosis of pulmonary carcinoid tumor. Hence, it could be reserved as a second line imaging modality. Further clinical randomized studies are necessary to establish the exact role of SRS in pulmonary carcinoid tumors.

**References**


